Skip to main content

Table 1 Disease transition probabilities for the high burden countries analyzed

From: Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries

Parameter

Probability of event/28 days, % (SE)

[Source]

Sputum culture conversion on BR, 0–8 weeks (log-normal)

 Scale parameter

4.99 (0.21)

Placebo-controlled phase II clinical trial C208 [12]

 Shape parameter

0.73 (0.11)

Placebo-controlled phase II clinical trial C208 [12]

Sputum culture conversion on BR, 8–24 weeks (log-normal)

 Scale parameter

5.68 (0.40)

Placebo-controlled phase II clinical trial C208 [12]

 Shape parameter

1.90 (0.27)

Placebo-controlled phase II clinical trial C208 [12]

Sputum culture conversion on BR, ≥24 weeks (log-normal)

 Scale parameter

8.28 (1.09)

Placebo-controlled phase II clinical trial C208 [12]

 Shape parameter

2.70 (0.82)

Placebo-controlled phase II clinical trial C208 [12]

Subsequent MDR-TB

 Hazard ratio of subsequent MDR-TB (vs. initial MDR-TB)

0.54 (0.17)

Open-label, phase II clinical trial C209 [13]

Other events

 Probability of reversion

1 (0.30)

Placebo-controlled phase II clinical trial C208 [12]

 Probability of death

MDR-TB, no cure

2.21

[34, 35]

MDR-TB, cure

0.32

[34, 35]

XDR-TB, no cure

2.69

[34, 35]

XDR-TB, cure

0.39

[34, 35]

Treatment effect

 Hazard ratio of bedaquiline (sputum culture conversion)

2.44 (0.57)

Placebo-controlled phase II clinical trial C208 [12]

 Hazard ratio of bedaquiline (relapse)

0.32 (0.25)

Placebo-controlled phase II clinical trial C208 [12]

 Hazard ratio (XDR-TB)

0.40 (0.11)

Open-label, phase II clinical trial C209 [13]

 

Estoniaa

Russiab

South Africaa

Perua

Chinaa

Philippinesa

Indiaa

Probability of loss to follow-up, % (SE)

1.4 (4.1)

1.5 (0.3)

1.4 (0.4)

1.5 (0.8)

0.6 (0.7)

3.4 (1.6)

1.2 (0.6)

  1. SOURCE: (a): [14]; (b): [15]
  2. BR background regimen, MDR-TB multidrug-resistant tuberculosis, SE standard error, XDR-TB extensively drug-resistant tuberculosis